A double-blind comparison of some analgesic and gastrointestinal effects of nalbuphine and pethidine was performed in 28 women undergoing laparoscopic sterilisation. The opioid was given as an initial loading dose prior to the induction of general anaesthesia and further doses were given on demand in the postoperative period to achieve and maintain adequate pain relief. Gastric emptying in the immediate postoperative period was also assessed in each patient by measuring the rate of absorption of orally administered paracetamol. Nalbuphine was equally effective as pethidine as a postoperative analgesic, but may have been a less effective supplement to anaesthesia in the doses used in this study. Gastric emptying was profoundly depressed in all patients irrespective of which analgesic was used.
Nalbuphine is a new opioid analgesic of the phenanthrene series structurally similar both to naloxone and to the strong agonist oxymorphone. On the basis of animal studies it has been classified as a kappa (k) agonist, and mu (lA) antagonist. Initial clinical investigations in man show that it shares the generaHy attractive characteristics of analgesics of the agonist-antagonist group, 1-3 but is distinguished from drugs such as butorphanol (Stadol) and pentazocine (Fortral) by the virtual absence of cardiovascular side-effects 4 and a low incidence of psychotomimetic effects. 1. 5 Both animal 6 and human 7 studies suggest also that nalbuphine has relatively less inhibitory effects on gastrointestinal motility than the pure agonists such as morphine and pethidine. These features commend nalbuphine for consideration as an alternative to the pure agonist opioids in obstetrics, or in other clinical circumstances where the possibility of relative or absolute overdosage exists and where inhibition of gastrointestinal motility is potentially dangerous.
This preliminary study was designed to compare nalbuphine and pethidine with regard to anaesthetic, analgesic and gastrointestinal effects in a young female population undergoing minor surgery.
PATIENTS AND METHODS
The approval of the Ethics Committee was obtained for this study which was carried out at the National Women's Hospital, Auckland. Twenty-eight fit women (ASA I or II) who were to undergo elective laparoscopic tubal ligation (Hulka clip) consented to participate. None had a history of hepatic or renal disease, and none had recent intake of any analgesic drugs.
The study was conducted double-blind. Uniquely numbered but otherwise identical ampoules containing either nalbuphine 21 mg in 2.1 ml or pethidine 150 mg in 2.1 ml were prepared sterile by the hospital pharmacy, and dispensed in random sequence as required. Matched ampoules were available in the event of more than one being needed for any individual patient. These analgesic concentrations were chosen as being approximately equipotent on the basis of preliminary open studies.
After a fast of at least three hours each woman was given oral diazepam (approx. 0.15 mg/kg) as premedication one hour before surgery. The same sequence was followed in each case: an intravenous cannula was inserted into a convenient arm vein and 1.3 ml of test analgesic was injected over 30 seconds. After a one-minute delay, anaesthesia was induced using intravenous thiopentone (given until the lash reflex was abolished), and the patient intubated following intravenous suxamethonium (1-1.5 mg/kg). Ventilation was maintained throughout the procedure with halothane 0.50/0 in oxygen 33% with nitrous oxide, and further intermittent doses of thiopentone or suxamethonium (25 mg per dose) were to be given if the patient appeared awake or moved in response to surgery. Atropine 0.3-0.6 mg IV was given to treat bradycardia. Following induction, a second intravenous cannula (18 G) for blood sampling purposes was inserted into a large antecubital vein, flushed with heparin and then capped.
Pain relief after operation was provided by further intravenous doses of the test drug. On wakening and then at 30 minute intervals over the next four hours, all patients were asked whether they were in pain and if so, whether it was mild, moderate or severe. Pain intensity was recorded on a simple 0-3 ordinal scale, and any woman reporting moderate or severe pain was given a further 0.3 ml of the test analgesic IV. The effect of this injection was assessed after 15 minutes when it was repeated as necessary.
Gastric emptying in the postoperative period was estimated by measuring the rate of absorption of orally administered paracetamol, as described and validated by Nimmo. 8 Thirty minutes after wakening each patient was given 1.5 g paracetamol in 50 ml water, and 5 ml blood samples for paracetamol assay taken at 0, 30, 60, 90, 120, 150, 180, 210 and 240 minutes. Patients were nursed in the supine or left lateral position for the entire study period,9 any who vomited were removed from the trial and given a parenteral antiemetic.
The blood samples were collected into plain glass tubes, centrifuged, and the plasma stored at -20 DC until assayed. Manual analysis of paracetamol was performed using a Syra (Syntex Co.) enzyme immunoassay kit. The kit procedure was altered such that the measure time was 45 seconds and only one buffer dilution of the sample was carried out. The range of linearity was 5-100 I1molll and the within-run coefficient of variation was 9.2% at 37 I1molll (N = 15). A Syra paracetamol control was diluted with kit buffer to 50l1molll immediately before use. Specimens determined as greater than 50 I1molll were also assayed using the normal kit procedure. The thiopentone and suxamethonium requirements of the two groups were compared by two-tailed t test and the Fisher exact probability test respectively, and other between-group comparisons were made using the Mann-Whitney U test. The Spearman rank correlation coefficient rs was calculated as a test of association between opioid dose and peak plasma paracetamol levels within each group. The null hypothesis was rejected if its probability was one in twenty or less (P<0.05).
RESULTS
Twenty-eight women entered the study, but in two cases the operation was changed. Details of the remaining twenty-six and the anaesthetic drugs given to them are summarised in Table 1. The two groups were similar with regard to age, weight and duration of surgery. The average thiopentone dose in the nalbuphine group was larger than in the pethidine group, but this difference was not statistically significant. No patient in either group required additional doses of thiopentone after induction, but a significantly higher proportion of those patients receiving nalbuphine required supplementary doses of suxamethonium during the procedure (P=0.05).
There was a modest but fairly uniform requirement for pain relief after operation despite the pre-operative intravenous bolus of opioid: 12 of the 26 patients admitted to moderate or severe pain on awakening, only three were quite pain-free. In all, 18 of the 26 patients required supplementary analgesia at some stage in the postoperative period. Median pain scores for the two groups as reported on recovery and at 30 minute intervals thereafter are shown in Figure 1 together with accumulated average opioid requirement per patient.
Pain scores for the two groups were not significantly different at any stage, and showed a similar decline when either opioid analgesic was administered. There was a high initial analgesic demand in both groups, but little further need after 90 minutes. The average requirements for opioid in the first three hours after operation were nalbuphine 6.6 mg and pethidine 57 mg.
Plasma paracetamol levels were measured after ingestion for three hours, and in some cases, for four. There was no significant difference between the groups in mean paracetamol concentrations at any time: both groups showed very low blood levels which rose only slowly over the study period. There was no significant association between individual opioid dose and peak plasma paracetamol levels in either group. Mean paracetamol levels for the two groups, together with the individual levels within each group, are shown in Figures 2  and 3 respectively . first three hours.
Anaesthesia and Intensive Care, Vol. 14. No. 2, May, 1986 The incidence of vomiting in the study was surprisingly low in both groups: despite the absence of any prophylactic antiemetic only two women in each group vomited after wakening -one before, and three after receiving the paracetamol.
DISCUSSION
The results of this study show that in the management of moderate postoperative pain, nalbuphine and pethidine are both effective and in this case indistinguishable at the dose levels chosen (the plasma paracetamol levels were so low that it is unlikely to have contributed to the pain relief in either group). The apparent analgesic equivalence (defined in terms of the cumulative dose totals necessary to maintain all patients together either pain-free or nearly so), was nalbuphine 20 mg = pethidine 150 mg. This estimate is in general agreement with the results obtained by Sprigge and Otton 10 who used a patient-controlled intravenous infusion system in 18 patients after general and gynaecological surgery and found that nalbuphine 3 mg appeared to be equipotent with pethidine 20 mg. The only other published comparison between these two drugs was by Waye and Braunfield. " In that study nalbuphine (given as an initial dose of 10 mg with subsequent 5 mg increments) did not appear to be as effective in relieving discomfort induced by colonoscopy as pethidine (50 mg initially, then 25 mg as necessary). Given the equivalence of the dose ratio in postoperative analgesic effect, it is of interest that following the preinduction 'loading' dose of opioid, those patients receiving nalbuphine were more likely to need extra doses of suxamethonium to maintain adequate operating conditions than were those who had received pethidine. In view of the fact that this difference only just reaches statistical significance, caution is needed in its evaluation but it seems reasonable to postulate that the nalbuphine was less effective as an anaesthetic supplement in the doses used. The higher average thiopentone requirement (and shorter median recovery interval) in the nalbuphine group would be consistent with this interpretation. It is unlikely that the difference is due simply to different time-courses of effect of the two analgesics since Sprigge and Otten 10 noted no difference in onset time. Studies on nalbuphine supplementation of anaesthesia in dogs 12 have demonstrated that even at very high dose nalbuphine is less able to substitute for inhalational anaesthetic agents than a pure agonist such as fentanyl, and volunteer studies in man have also demonstrated a ceiling to the analgesic as well as respiratory depressant effects of nalbuphine. '3 Nalbuphine may well be a less suitable choice as supplement to general anaesthesia than a pure agonist analgesic, especially in more major surgery where intense opioid effect is necessary.
The pattern of plasma paracetamol levels characteristic of normal gastric emptying is now well established, with peak levels being recorded at about 30 minutes after ingestion. 8 Gastric emptying was markedly inhibited in both nalbuphine and pethidine-treated patients in this study, although without an adequate Anaesthesia and Intensive Care. Vo!. 14 opioid-free control group the extent to which this effect is due to these drugs cannot be determined. Recent animal studies suggest that in the case of systemically administered opioids, 'lA' antagonist and 'k' agonist drugs would have less effect than pethidine. 14 In our study, however, not only was there no difference between the drugs, but at the level of the individual patient there appeared to be no relationship between dosage and gut effect. This suggests that other (probably nonanaesthetic)IS factors were also important and are likely to include anticholinergic medication and the effects of the surgery itself. In practice it seems that simple substitution of an agonistantagonist analgesic such as nalbuphine for a pure agonist such as pethidine does not produce a worthwhile improvement in gastric emptying following laparoscopic sterilisation.
